Biologics Consulting

Biologics Consulting

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Biologics Consulting is a veteran, employee-owned (ESOP) regulatory consultancy founded in 1993 by former FDA officials. It provides integrated, multidisciplinary strategy and operational support for drug, biologic, device, and combination product development, boasting a track record of over 4,700 projects for clients in 58+ countries. The firm differentiates itself through a team of 65+ regulatory experts, including former FDA professionals, offering services from regulatory strategy and submission authoring to full staff augmentation. Its client-focused approach aims to de-risk development and speed market entry for innovative therapies.

BiologicsRegulatory AffairsDrug Delivery

Technology Platform

Proprietary regulatory consulting methodology and integrated service model leveraging deep expertise of former FDA officials and multidisciplinary teams. Focus on regulatory strategy, submission authoring, and operational support across drugs, biologics, devices, and combination products.

Opportunities

Growing demand for regulatory expertise driven by increasing complexity in novel therapeutic areas like cell & gene therapy, mRNA, and combination products.
Expansion opportunities in serving international biotech firms seeking U.S.
market access and in providing end-to-end regulatory support for virtual or lean biotech companies.

Risk Factors

High dependence on retaining specialized talent (former FDA officials) in a competitive market.
Revenue vulnerability to cyclical downturns in biotech funding, which may reduce client spending on consulting services.
Reputational risk associated with the outcome of client regulatory submissions.

Competitive Landscape

Competes with large global CROs (e.g., IQVIA, Parexel) offering regulatory services, specialized boutique regulatory consultancies, and the in-house regulatory teams of large pharma. Differentiation is based on deep FDA-specific expertise, former agency personnel, employee-owned (ESOP) client alignment, and a focused, multidisciplinary approach.